Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer

Eur J Cancer. 2002 Nov:38 Suppl 6:S52-4. doi: 10.1016/s0959-8049(02)00285-x.
No abstract available

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Cross-Over Studies
  • Double-Blind Method
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Letrozole
  • Neoplasm Metastasis
  • Nitriles / therapeutic use*
  • Progestins / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Tamoxifen / therapeutic use*
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Enzyme Inhibitors
  • Nitriles
  • Progestins
  • Triazoles
  • Tamoxifen
  • Letrozole